Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
Stopped Based on tolerability findings at the low dose level thus far, continuation of dosing or even dose escalation is not possible.
Conditions
Interventions
Sponsor
Dynacure